Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.

Aethlon Medical, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SAN DIEGO , OCT. 7, 2025 /PRNEWSWIRE/ -- AETHLON MEDICAL, INC. ("AETHLON" OR THE "COMPANY") (NASDAQ: AEMD) TODAY PROVIDED OBSERVATIONS ON THE PRELIMINARY CHANGES IN EXTRACELLULAR VESICLE (EV), MICRORNA AND LYMPHOCYTE COUNTS IN THE FIRST PATIENT COHORT IN ITS ONGOING ONCOLOGY CLINICAL TRIAL IN AUSTRALIA. THE STUDY IS A SAFETY, FEASIBILITY, AND DOSE-FINDING TRIAL EVALUATING THE COMPANY'S HEMOPURIFIER (HP) IN PATIENTS WITH CANCER NOT RESPONDING TO ANTI-PD-1 THERAPY.

AETHLON MEDICAL'S HEMOPURIFIER SHOWS CHANGES IN EXTRACELLULAR VESICLES, EXTRACELLULAR MICRORNAS, AND T CELL NUMBERS IN AUSTRALIAN ONCOLOGY CLINICAL TRIAL

SAN DIEGO , SEPT. 4, 2025 /PRNEWSWIRE/ -- AETHLON MEDICAL, INC. ("AETHLON" OR THE "COMPANY") (NASDAQ: AEMD), A MEDICAL THERAPEUTIC COMPANY FOCUSED ON DEVELOPING PRODUCTS TO TREAT CANCER AND LIFE-THREATENING INFECTIOUS DISEASES, TODAY ANNOUNCED THE PRICING OF A PUBLIC OFFERING OF AN AGGREGATE OF 5,000,000 SHARES OF ITS COMMON STOCK (OR PRE-FUNDED WARRANTS IN LIEU THEREOF) AND WARRANTS TO PURCHASE UP TO 5,000,000 SHARES OF COMMON STOCK AT A COMBINED PUBLIC OFFERING PRICE OF $0.90 PER SHARE (OR PRE-FUNDED WARRANT) AND ACCOMPANYING WARRANT.

AETHLON MEDICAL ANNOUNCES PRICING OF $4.5 MILLION PUBLIC OFFERING

AUSTRALIAN CANCER TRIAL ADVANCES WITH FIRST COHORT COMPLETE, AMENDED PROTOCOL, AND PROMISING PRECLINICAL DATA PUBLISHED; OPERATING EXPENSES CUT BY 32% CONFERENCE CALL TO BE HELD TODAY AT 4:30 P.M. ET SAN DIEGO , AUG. 13, 2025 /PRNEWSWIRE/ -- AETHLON MEDICAL, INC. (THE COMPANY OR AETHLON) (NASDAQ: AEMD), A MEDICAL THERAPEUTIC COMPANY FOCUSED ON DEVELOPING PRODUCTS TO TREAT CANCER AND LIFE-THREATENING INFECTIOUS DISEASES, TODAY REPORTED FINANCIAL RESULTS FOR ITS FISCAL FIRST QUARTER ENDED JUNE 30, 2025, AND PROVIDED AN UPDATE ON RECENT DEVELOPMENTS.

AETHLON MEDICAL ANNOUNCES FINANCIAL RESULTS FOR THE FISCAL FIRST QUARTER ENDED JUNE 30, 2025, AND PROVIDES CORPORATE UPDATE

SAN DIEGO , AUG. 5, 2025 /PRNEWSWIRE/ -- AETHLON MEDICAL, INC. (NASDAQ: AEMD), A MEDICAL THERAPEUTIC COMPANY FOCUSED ON DEVELOPING PRODUCTS TO TREAT CANCER AND LIFE THREATENING INFECTIOUS DISEASES, TODAY ANNOUNCED THAT IT WILL ISSUE FINANCIAL RESULTS FOR ITS FISCAL FIRST QUARTER ENDED JUNE 30, 2025, AT 4:15 P.M. ET ON WEDNESDAY, AUGUST 13, 2025.

AETHLON MEDICAL TO RELEASE FISCAL FIRST QUARTER FINANCIAL RESULTS AND HOST CONFERENCE CALL ON AUGUST 13, 2025

SAN DIEGO , JULY 15, 2025 /PRNEWSWIRE/ -- AETHLON MEDICAL, INC. (NASDAQ: AEMD), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING THE INVESTIGATIONAL AETHLON HEMOPURIFIER, AN EXTRACORPOREAL DEVICE FOR ONCOLOGY AND OTHER INDICATIONS, TODAY ANNOUNCED THAT THE INDEPENDENT DATA SAFETY MONITORING BOARD (DSMB) OVERSEEING ITS ONGOING CLINICAL TRIAL AEMD-2022-06 HAS COMPLETED ITS SCHEDULED SAFETY REVIEW AND RECOMMENDED ADVANCING TO THE NEXT PATIENT COHORT WITHOUT MODIFICATION. THE TRIAL, TITLED "SAFETY, FEASIBILITY, AND DOSE-FINDING STUDY OF AETHLON HEMOPURIFIER IN PATIENTS WITH SOLID TUMORS WHO HAVE STABLE OR PROGRESSIVE DISEASE WHILE ON A TREATMENT THAT INCLUDES PEMBROLIZUMAB OR NIVOLUMAB", IS BEING CONDUCTED TO ASSESS THE HEMOPURIFIER'S SAFETY, FEASIBILITY, AND OPTIMAL DOSING.

AETHLON MEDICAL, INC. ANNOUNCES POSITIVE DATA SAFETY MONITORING BOARD REVIEW AND RECOMMENDATION TO ADVANCE TO NEXT CLINICAL TRIAL COHORT

THREE PATIENTS TREATED IN HEMOPURIFIER CANCER TRIAL; INDIAN REGULATORY APPROVAL ACHIEVED; OPERATING EXPENSES REDUCED; R&D ADVANCES SUPPORT EXPANDED INDICATIONS INCLUDING LONG COVID CONFERENCE CALL TO BE HELD TODAY AT 4:30 P.M. ET SAN DIEGO , JUNE 26, 2025 /PRNEWSWIRE/ -- AETHLON MEDICAL, INC. (THE COMPANY OR AETHLON) (NASDAQ: AEMD), A MEDICAL THERAPEUTIC COMPANY FOCUSED ON DEVELOPING PRODUCTS TO TREAT CANCER AND LIFE-THREATENING INFECTIOUS DISEASES, TODAY REPORTED FINANCIAL RESULTS FOR ITS FISCAL FOURTH QUARTER ENDED MARCH 31, 2025, AND PROVIDED AN UPDATE ON RECENT DEVELOPMENTS.

AETHLON MEDICAL ANNOUNCES FINANCIAL RESULTS FOR THE FISCAL FOURTH QUARTER ENDED MARCH 31, 2025, AND PROVIDES CORPORATE UPDATE

SAN DIEGO , JUNE 20, 2025 /PRNEWSWIRE/ -- AETHLON MEDICAL, INC.(NASDAQ: AEMD), A MEDICAL THERAPEUTIC COMPANY FOCUSED ON DEVELOPING PRODUCTS TO TREAT CANCER AND LIFE THREATENING INFECTIOUS DISEASES, TODAY ANNOUNCED THAT IT WILL ISSUE FINANCIAL RESULTS FOR ITS FISCAL FOURTH QUARTER ENDED MARCH 31, 2025, AT 4:15 P.M. ET ON THURSDAY, JUNE 26, 2025.

AETHLON MEDICAL TO RELEASE FISCAL FOURTH QUARTER FINANCIAL RESULTS AND HOST CONFERENCE CALL ON JUNE 26, 2025

SECOND PATIENT IN FIRST COHORT ENROLLED AND TREATED AT THE ROYAL NORTH SHORE HOSPITAL/UNIVERSITY OF SYDNEY AETHLON ADVANCES HEMOPURIFIER STUDY IN SOLID TUMORS NOT RESPONDING TO ANTI-PD-1 ANTIBODIES SAN DIEGO , JUNE 18, 2025 /PRNEWSWIRE/ -- AETHLON MEDICAL, INC. (NASDAQ: AEMD), A MEDICAL THERAPEUTIC COMPANY FOCUSED ON DEVELOPING PRODUCTS TO TREAT CANCER AND LIFE-THREATENING INFECTIOUS DISEASES, TODAY ANNOUNCED A SIGNIFICANT MILESTONE: THE TREATMENT OF THE SECOND PATIENT WITH THEHEMOPURIFIER IN ITS AUSTRALIAN SAFETY, FEASIBILITY AND DOSE-FINDING CLINICAL TRIAL OF THE HEMOPURIFIER. THIS TRIAL IS DESIGNED FOR PATIENTS WITH SOLID TUMORS WHO HAVE STABLE OR PROGRESSIVE DISEASE DURING ANTI-PD-1 MONOTHERAPY TREATMENT, SUCH AS KEYTRUDA (PEMBROLIZUMAB) OR OPDIVO (NIVOLUMAB) (AEMD-2022-06 HEMOPURIFIER STUDY).

AETHLON MEDICAL TREATS SECOND PATIENT IN AUSTRALIAN HEMOPURIFIER CANCER TRIAL

POSTER PRESENTATION REVIEWS THE HEMOPURIFIER  AFFINITY RESIN'S A BILITY TO BIND EXTRACELLULAR VESICLES IN LONG COVID SAMPLES SAN DIEGO , JUNE 9, 2025 /PRNEWSWIRE/ -- AETHLON MEDICAL, INC. (NASDAQ: AEMD), A MEDICAL THERAPEUTIC COMPANY FOCUSED ON DEVELOPING PRODUCTS TO TREAT CANCER AND LIFE-THREATENING INFECTIOUS DISEASES, TODAY ANNOUNCED THAT AN ABSTRACT HAS BEEN ACCEPTED FOR POSTER PRESENTATION AT THE KEYSTONE SYMPOSIUM ON LONG COVID AND OTHER POST-ACUTE INFECTION SYNDROMES BEING HELD AT ELDORADO HOTEL & SPA, SANTA FE, NM, UNITED STATES, AUGUST 10-13,2025 (HTTPS://WWW.KEYSTONESYMPOSIA.ORG/CONFERENCES/CONFERENCE-LISTING/MEETING/PROGRAM-HIGHLIGHTS/F12026). LONG COVID REFERS TO PERSISTENT SYMPTOMS FOLLOWING ACUTE SARS-COV-2 INFECTION (COVID-19).

AETHLON MEDICAL TO PRESENT NEW PRE-CLINICAL DATA AT THE KEYSTONE SYMPOSIUM ON LONG COVID AND OTHER POST-ACUTE INFECTION SYNDROMES

RESULTS REINFORCE THE CURRENT AUSTRALIAN ONCOLOGY CLINICAL TRIAL AND SUPPORT INVESTIGATION OF THE HEMOPURIFIER ACROSS MULTIPLE INDICATIONS SAN DIEGO , MAY 14, 2025 /PRNEWSWIRE/ --AETHLON MEDICAL, INC. (NASDAQ: AEMD), A MEDICAL THERAPEUTIC COMPANY FOCUSED ON DEVELOPING PRODUCTS TO TREAT CANCER AND LIFE-THREATENING INFECTIOUS DISEASES, TODAY ANNOUNCED THE PUBLICATION ( HTTPS://WWW.BIORXIV.ORG/CGI/CONTENT/SHORT/2025.05.09.652772V1 ) OF A PRE-CLINICAL EX VIVO STUDY IN PRE-PRINT VEHICLE BIORXIV, ENTITLED, "EX VIVO REMOVAL OF CD41 POSITIVE PLATELET MICROPARTICLES FROM PLASMA BY A MEDICAL DEVICE CONTAINING A GALANTHUS NIVALIS AGGLUTININ (GNA) AFFINITY RESIN." AETHLON MEDICAL'S HEMOPURIFIER IS A THERAPEUTIC BLOOD FILTRATION SYSTEM DESIGNED TO BIND AND REMOVE HARMFUL EXTRACELLULAR VESICLES (EVS OR EXOSOMES) AND LIFE-THREATENING VIRUSES FROM BLOOD AND OTHER BIOLOGICAL FLUIDS, PROPERTIES THAT SUPPORT ITS EVALUATION NOT ONLY IN ONCOLOGY AND INFECTIOUS DISEASES, BUT ALSO IN THE ORGAN TRANSPLANTATION AND OTHER AREAS OF SIGNIFICANT UNMET MEDICAL NEED.

AETHLON MEDICAL ANNOUNCES PUBLICATION OF PRECLINICAL DATA SHOWING ABILITY OF THE HEMOPURIFIER TO REMOVE PLATELET-DERIVED EXTRACELLULAR VESICLES FROM PLASMA

Aethlon Medical, Inc.

AEMD

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Aethlon Medical, Inc.

AEMD.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

AEMD